OMEROS CORP — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Gregory A. Demopulos, M.D. (CEO) granted 500,000 stock options on October 2026 at an undisclosed exercise price, vesting over 4 years subject to dual conditions: (1) continuous employment, and (2) stock price achieving $25, $30, $35, and $40 hurdles (125,000 shares per tranche). Options expire October 2031. The grant structure includes accelerated vesting upon Change in Control at relevant price levels and post-termination exercise rights.
Why this rating
Standard CEO equity grant. 500K options at ~$172M market cap is material for dilution (~0.3% if fully exercised at current levels), but is routine executive compensation disclosure, not a business event or operational change.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.